Effects of a Berry Oil Cream on Atopic Eczema and Skin

NCT ID: NCT04085549

Last Updated: 2021-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

83 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-09

Study Completion Date

2020-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Atopic eczema is a chronic inflammatory skin disease associated with itch and inflammatory lesions in typical skin areas. The objective of this study is to investigate the effects of a cream containing berry and plant oils and humectants on atopic eczema and dry skin.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atopic Dermatitis Eczema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Study has two parts. In part 1 the participants, care provider and outcome assessor know which treatment is given to each skin area. In part 2 participant, care provider, investigator and outcome assessor do not know which treatment is given to each skin area. Masking is done by identical cream tubes.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Berry Oil Cream

Study part 1: Administered to a chosen eczema lesion on randomized body half 1-2 times/d or more frequently (use reported to study logbook) for two weeks. Also administered to forearm (randomized body half) twice/d for two weeks. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.

Group Type EXPERIMENTAL

Berry Oil Cream

Intervention Type DEVICE

Cream containing berry and plant oils and humectants; a medical device product in development

Control

Study part 1: A chosen eczema lesion on randomized body half is an untreated control for two weeks. Also one forearm (on randomized body half) is a control with no treatment for two weeks.

Group Type NO_INTERVENTION

No interventions assigned to this group

Reference cream

A commercial reference cream, not containing berry and plant oils. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.

Group Type ACTIVE_COMPARATOR

Reference Cream

Intervention Type OTHER

Commercial refence cream not containing berry and plant oils.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Berry Oil Cream

Cream containing berry and plant oils and humectants; a medical device product in development

Intervention Type DEVICE

Reference Cream

Commercial refence cream not containing berry and plant oils.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Atopic Eczema (mild or medium severity)

Exclusion Criteria

* Other serious skin conditions (for example psoriasis)
* Known hypersensitivity to ingredients of the study creams
* Medication seriously affecting immune function
Minimum Eligible Age

12 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cliniscan Ltd

UNKNOWN

Sponsor Role collaborator

Petra Larmo

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Petra Larmo

Ph.D., R&D Manager

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Risto Oksman, MD

Role: PRINCIPAL_INVESTIGATOR

Cliniscan Ltd

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mehiläinen (Private Clinic)

Turku, , Finland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Finland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BOAE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.